Dermapharm Holding SE (ETR:DMP)
Germany
· Delayed Price · Currency is EUR | Market Cap | 2.27B |
| Revenue (ttm) | 1.18B |
| Net Income (ttm) | 132.41M |
| Shares Out | 49.54M |
| EPS (ttm) | 2.46 |
| PE Ratio | 18.60 |
| Forward PE | 18.34 |
| Dividend | 0.88 (1.94%) |
| Ex-Dividend Date | Jun 29, 2026 |
| Volume | 19,619 |
| Average Volume | 27,119 |
| Open | 45.85 |
| Previous Close | 45.45 |
| Day's Range | 44.85 - 45.85 |
| 52-Week Range | 31.70 - 47.25 |
| Beta | 0.87 |
| RSI | 58.63 |
| Earnings Date | May 13, 2026 |
About Dermapharm Holding SE
Dermapharm Holding SE, together with its subsidiaries, manufactures and sells off-patent branded pharmaceutical products in Germany, Italy, France, Austria, Switzerland, Spain, Portugal, the Netherlands, Croatia, Poland, Ukraine, the United States, and China. The company operates through three segments: Branded Pharmaceuticals; Other Healthcare Products; and Parallel Import Business. It offers branded generics, OTC products, non-prescription healthcare products, and herbal extracts and parallel-imported originator pharmaceuticals. The company a... [Read more]
Financial Performance
In 2025, Dermapharm Holding SE's revenue was 1.18 billion, a decrease of -1.43% compared to the previous year's 1.20 billion. Earnings were 132.41 million, an increase of 16.37%.
Financial StatementsNews
EQS-NVR: Dermapharm Holding SE: Release according to Article 41 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
EQS Total Voting Rights Announcement: Dermapharm Holding SE / Total Voting Rights Announcement Dermapharm Holding SE: Release according to Article 41 of the WpHG [the German Securities Trading Act] wi...
EQS-PVR: Dermapharm Holding SE: Publication of acquisition or disposal in respect of own shares according Sec. 40 para. 1 sent. 2 WpHG
EQS Voting Rights Announcement: Dermapharm Holding SE Dermapharm Holding SE: Publication of acquisition or disposal in respect of own shares according Sec. 40 para. 1 sent. 2 WpHG 07.04.2026 / 10:08 C...
Dermapharm Holding SE Earnings Call Transcript: Q4 2025
Revenue and adjusted EBITDA for 2025 met guidance, with margin improvements and strong cash flow. Growth is expected in 2026 from M&A, branded products, and international expansion, while restructuring and portfolio optimization continue to drive efficiency.
Dermapharm Holding SE Earnings Call Transcript: Q3 2025
Branded pharmaceuticals drove growth in Q3 2025, with strong international and Alargo Pharma performance. Portfolio optimization and restructuring improved margins, while guidance for full-year revenue and EBITDA is expected to be met, supported by seasonal strength in Q4.